Genematrix

Genematrix Debt

The Debt of Genematrix (109820.KQ) as of Nov 3, 2026 is 3.67 B KRW. In the previous year, Debt was 3.71 B KRW — a change of -1.06% (lower).

Debt

3.67 BKRW

YoY

-1.06%

Last updated:

In 2024, Genematrix's total debt was 3.67 B KRW, a -1.06% change from the 3.71 B KRW total debt recorded in the previous year.

The Genematrix Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
4.10 B KRW
Jan 1, 2018
7.82 B KRW
Jan 1, 2019
3.64 B KRW
Jan 1, 2020
3.64 B KRW
Jan 1, 2021
3.63 B KRW
Jan 1, 2022
3.61 B KRW
Jan 1, 2023
3.71 B KRW
Jan 1, 2024
3.67 B KRW
The Genematrix Debt history
YEARDebtYoY
3.67 BKRW-1.06%
3.71 BKRW+2.62%
3.61 BKRW-0.54%
3.63 BKRW-0.06%
3.64 BKRW+0.01%
3.64 BKRW-53.52%
7.82 BKRW+90.77%
4.10 BKRW0.00%
4.10 BKRW-69.38%
13.39 BKRW+261.85%
3.70 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genematrix Stock analysis

What does Genematrix do? Genematrix Inc develops RFMP genotyping technology for diagnosing hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus (HPV) within its pharmaceutical development segment. The company manufactures and sells liver-function examination reagents through its diagnostic medicine segment, while also importing and selling medical equipment and reagents. Customers for these products include healthcare providers and medical facilities requiring viral diagnostics and liver function testing. The pharmaceutical development segment targets laboratories focused on viral infection diagnosis, while the diagnostic medicine segment serves hospitals and clinics needing reagents for liver health assessments. Genematrix Inc's revenue streams come from sales of RFMP-based diagnostic tools for HBV, HCV, and HPV testing, alongside liver-function reagent sales. The company's diagnostic medicine segment generates income through the import and sale of medical equipment and reagents, catering to healthcare institutions. Its pharmaceutical development segment focuses on viral genotyping solutions for medical laboratories, creating a dual revenue model from both diagnostic products and equipment services. The company's products are sold to healthcare institutions requiring viral diagnostics and liver function testing. Pharmaceutical development customers include medical laboratories specializing in HBV, HCV, and HPV testing, while diagnostic medicine customers are hospitals and clinics using liver-function reagents. Genematrix Inc's business model relies on direct sales of its proprietary RFMP technology and imported medical equipment to these specialized healthcare segments without third-party distribution. Genematrix is one of the most popular companies on Eulerpool.

Debt Details

Understanding Genematrix's Debt Structure

Genematrix's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Genematrix's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Genematrix’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Genematrix’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Genematrix stock

Debt of Genematrix is 3.67 B KRW in 2024.

Debt of Genematrix changed from 3.71 B KRW to 3.67 B KRW, representing a -1.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Genematrix since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Genematrix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genematrix

All Key Metrics — Genematrix